


Ibuprofen

Cat. No.:	HY-78131		
CAS No.:	15687-27-1		
Molecular Formula:	C ₁₃ H ₁₈ O ₂		
Molecular Weight:	206.28		
Target:	COX; Apoptosis; Parasite		
Pathway:	Immunology/Inflammation; Apoptosis; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (484.78 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	4.8478 mL	24.2389 mL	48.4778 mL
	5 mM	0.9696 mL	4.8478 mL	9.6956 mL
	10 mM	0.4848 mL	2.4239 mL	4.8478 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers^{[1][2][5][8]}.

IC₅₀ & Target

COX-1

COX-2

	13 μM (IC_{50})	370 μM (IC_{50})								
In Vitro	<p>Ibuprofen (24 h) inhibits COX-1 and COX-2 activity with IC_{50} values of 13 μM and 370 μM^[1].</p> <p>Ibuprofen (500 μM, 48 h) inhibits cell proliferation and angiogenesis, and induces apoptosis in AGS cells (Adenocarcinoma gastric cell line)^[2].</p> <p>Ibuprofen (500 μM, 48 h) downregulates transcription of Akt, VEGF-A, PCNA, Bcl2, OCT3/4 and CD44 genes, but upregulates RNA levels of wild type P53 and Bax genes in AGS cell^[2].</p> <p>Ibuprofen (500 μM, 24 h) restores microtubule reformation, microtubule-dependent intracellular cholesterol transport, and induces extension of microtubules to the cell periphery in both cystic fibrosis (CF) cell models and primary CF nasal epithelial cells^[3].</p> <p>Ibuprofen (500 μM, 24 h) enhances UV-induced cell death in MCF-7 cells and MDA-MB-231 cells by a photosensitization process^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p>									
	<table border="1"> <tr> <td>Cell Line:</td> <td>AGS cells</td> </tr> <tr> <td>Concentration:</td> <td>100-1000 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h, 48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited AGS cell viability with IC_{50} values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h).</td> </tr> </table>	Cell Line:	AGS cells	Concentration:	100-1000 μM	Incubation Time:	24 h, 48 h	Result:	Inhibited AGS cell viability with IC_{50} values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h).	
Cell Line:	AGS cells									
Concentration:	100-1000 μM									
Incubation Time:	24 h, 48 h									
Result:	Inhibited AGS cell viability with IC_{50} values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h).									
In Vivo	<p>Ibuprofen (300 mg/kg; p.o.; daily, for 14 days) reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer^[5].</p> <p>Ibuprofen (60 mg/kg; i.h.; every second day for 15 days) reduces the risk of neuropathy in a rat model of chronic Oxaliplatin\square induced peripheral neuropathy^[6].</p> <p>Ibuprofen (20 mg/kg; p.o.; every 12 hours, 5 doses total) decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptations to exercise^[7].</p> <p>Ibuprofen (35 mg/kg; p.o.; twice daily) attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection^[8].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
	<table border="1"> <tr> <td>Animal Model:</td> <td>Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)^[5]</td> </tr> <tr> <td>Dosage:</td> <td>300 mg/kg, daily for 14 days</td> </tr> <tr> <td>Administration:</td> <td>Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)</td> </tr> <tr> <td>Result:</td> <td>Suppressed tumor growth, reduced presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.</td> </tr> </table>	Animal Model:	Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum) ^[5]	Dosage:	300 mg/kg, daily for 14 days	Administration:	Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)	Result:	Suppressed tumor growth, reduced presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.	
Animal Model:	Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum) ^[5]									
Dosage:	300 mg/kg, daily for 14 days									
Administration:	Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)									
Result:	Suppressed tumor growth, reduced presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.									
	<table border="1"> <tr> <td>Animal Model:</td> <td>Oxaliplatin\squareinduced peripheral neuropathy^[6]</td> </tr> <tr> <td>Dosage:</td> <td>60 mg/kg, every second day for 15 days</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection</td> </tr> <tr> <td>Result:</td> <td>Lowered sensory nerve conduction velocity (SNCV).</td> </tr> </table>	Animal Model:	Oxaliplatin \square induced peripheral neuropathy ^[6]	Dosage:	60 mg/kg, every second day for 15 days	Administration:	Subcutaneous injection	Result:	Lowered sensory nerve conduction velocity (SNCV).	
Animal Model:	Oxaliplatin \square induced peripheral neuropathy ^[6]									
Dosage:	60 mg/kg, every second day for 15 days									
Administration:	Subcutaneous injection									
Result:	Lowered sensory nerve conduction velocity (SNCV).									

CUSTOMER VALIDATION

- Cell Rep. 2019 Dec 17;29(12):3847-3858.e5.
- Chemosphere. 2019 Jun;225:378-387.
- Phytomedicine. 1 September 2022, 154427.
- EMBO Rep. 2022 Apr 11;e53932.
- Cells. 2022, 11(12), 1870.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Noreen Y, et al. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. *J Nat Prod.* 1998 Jan;61(1):2-7.
- [2]. Hassan Akrami, et al. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. *Tumour Biol.* 2015 May;36(5):3237-43.
- [3]. Sharon M Rymut, et al. Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. *Am J Physiol Lung Cell Mol Physiol.* 2016 Aug 1;311(2):L317-27.
- [4]. Emmanuelle Bignon, et al. Ibuprofen and ketoprofen potentiate UVA-induced cell death by a photosensitization process. *Sci Rep.* 2017 Aug 21;7(1):8885.
- [5]. Nathan D Pennock, et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. *J Immunother Cancer.* 2018 Oct 1;6(1):98.
- [6]. Thomas Krøigård, et al. Protective effect of ibuprofen in a rat model of chronic oxaliplatin-induced peripheral neuropathy. *Exp Brain Res.* 2019 Oct;237(10):2645-2651.
- [7]. Sarah Ilkhanipour Rooney, et al. Ibuprofen Differentially Affects Supraspinatus Muscle and Tendon Adaptations to Exercise in a Rat Model. *Am J Sports Med.* 2016 Sep;44(9):2237-45.
- [8]. M W Konstan, et al. Ibuprofen attenuates the inflammatory response to *Pseudomonas aeruginosa* in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. *Am Rev Respir Dis.* 1990 Jan;141(1):186-92.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA